SG11202010911WA - Methods and compositions for treating chronic urticaria - Google Patents

Methods and compositions for treating chronic urticaria

Info

Publication number
SG11202010911WA
SG11202010911WA SG11202010911WA SG11202010911WA SG11202010911WA SG 11202010911W A SG11202010911W A SG 11202010911WA SG 11202010911W A SG11202010911W A SG 11202010911WA SG 11202010911W A SG11202010911W A SG 11202010911WA SG 11202010911W A SG11202010911W A SG 11202010911WA
Authority
SG
Singapore
Prior art keywords
compositions
methods
treating chronic
chronic urticaria
urticaria
Prior art date
Application number
SG11202010911WA
Other languages
English (en)
Inventor
Christopher Robert Bebbington
Nenad Tomasevic
Henrik Rasmussen
Original Assignee
Allakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allakos Inc filed Critical Allakos Inc
Publication of SG11202010911WA publication Critical patent/SG11202010911WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11202010911WA 2018-05-04 2019-05-03 Methods and compositions for treating chronic urticaria SG11202010911WA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862667242P 2018-05-04 2018-05-04
US201962788719P 2019-01-04 2019-01-04
US201962797817P 2019-01-28 2019-01-28
US201962803211P 2019-02-08 2019-02-08
US201962806657P 2019-02-15 2019-02-15
PCT/US2019/030523 WO2019213468A1 (en) 2018-05-04 2019-05-03 Methods and compositions for treating chronic urticaria

Publications (1)

Publication Number Publication Date
SG11202010911WA true SG11202010911WA (en) 2020-12-30

Family

ID=68386174

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010911WA SG11202010911WA (en) 2018-05-04 2019-05-03 Methods and compositions for treating chronic urticaria

Country Status (11)

Country Link
US (1) US20210246205A1 (https=)
EP (1) EP3788078A4 (https=)
JP (2) JP2021523117A (https=)
KR (1) KR20210005245A (https=)
CN (1) CN112384535A (https=)
AU (1) AU2019262167A1 (https=)
BR (1) BR112020022236A2 (https=)
CA (1) CA3099338A1 (https=)
MX (1) MX2020011377A (https=)
SG (1) SG11202010911WA (https=)
WO (1) WO2019213468A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200016232A (ko) 2017-05-05 2020-02-14 알라코스 인크. 알레르기성 안구 질환을 치료하기 위한 방법 및 조성물
JP2023541217A (ja) * 2020-07-10 2023-09-29 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド 抗ＩｇＥ改変抗体及びその適用
KR102803012B1 (ko) * 2022-08-11 2025-04-30 오씨아이 주식회사 석유계 고연화점 피치의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201603127WA (en) * 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
KR102311761B1 (ko) * 2013-12-09 2021-10-13 알라코스 인크. 항-Siglec-8 항체 및 그의 사용 방법
CA2939931C (en) * 2014-02-28 2025-04-22 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8
US10604577B2 (en) * 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis

Also Published As

Publication number Publication date
MX2020011377A (es) 2020-11-24
JP2021523117A (ja) 2021-09-02
CN112384535A (zh) 2021-02-19
EP3788078A1 (en) 2021-03-10
BR112020022236A2 (pt) 2021-02-02
CA3099338A1 (en) 2019-11-07
KR20210005245A (ko) 2021-01-13
US20210246205A1 (en) 2021-08-12
WO2019213468A1 (en) 2019-11-07
JP2024045612A (ja) 2024-04-02
EP3788078A4 (en) 2022-03-02
AU2019262167A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
ZA202006627B (en) Methods and compositions for treating cancer
IL272877A (en) SHP2 inhibitory compositions and methods for cancer treatment
GB2578539B (en) Compositions and methods for preventing or treating muscle conditions
PT3496739T (pt) Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar
IL286350A (en) Preparations and methods for the treatment of cancer
IL274837A (en) Methods and preparations for the treatment of cancer
IL288914A (en) Preparations and methods for the treatment of cancer
IL269637A (en) Preparations and methods for the treatment of synovial diseases
ZA202104870B (en) Methods and compositions for treating cancer
IL285886A (en) Preparations and methods for the treatment of laminopathy
IL325803A (en) Materials and methods for cancer treatment
SG11202012435UA (en) Compositions and methods for treating cancer
IL285796A (en) Methods and preparations for the treatment of cancer
IL280413A (en) Bismuth-thiol preparations and wound treatment methods
IL271256A (en) Preparations and methods for the treatment of teopathy
IL278814A (en) Methods and preparations for the treatment of pulmonary hypertension
DK3658142T3 (en) Compositions and methods for treating galactosemia
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
ZA201804478B (en) Methods and compositions for treating gastric ulcers
IL261010B (en) Compositions and methods for treating chronic wounds
IL287982A (en) Preparations and methods for the treatment of cancer
IL286153A (en) Methods and preparations for the treatment of cancer
SG11202010911WA (en) Methods and compositions for treating chronic urticaria
IL277463A (en) Vehicles and methods for treating itch
IL272782A (en) Preparations and methods for the treatment of cancer